Sign In
Free Newsletter
Novo Nordisk launches Wegovy subscription plan with savings
The new option offers lower monthly pricing for self-pay patients via telehealth platforms, such as Weight Watchers, LifeMD, Hims & Hers and Sesame, to expand access to GLP-1 weigh loss drugs.
ShopRite launches GLP-1 wellness starter kits
Customers filling their first prescription will receive product samples, nutrition guides and recipes to support patients beginning weight loss medications.
NJBIZ Looking Ahead 2026: Shifting customer preferences
New Jersey leaders predict 2026 customers will seek transparency, flexibility, digital access and value across cannabis, health and retail sectors.
BD pledges $110M to expand Nebraska syringe manufacturing
BD plans to invest $110 million to upgrade syringe manufacturing in Nebraska, expanding capacity, adding jobs and supporting demand for biologics and GLP-1 drugs.
Novo Nordisk’s Wegovy weight loss pill hits US market
The pharma launched a once-daily alternative to its injections, available nationwide after FDA approval at 70,000 pharmacies with starting doses priced at $149 per month.
FDA approves Wegovy weight loss pill from Novo Nordisk
The first oral GLP-1 obesity drug will launch in the U.S. at a $149 starting price in 2026.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Novo Nordisk to cut 9,000 jobs in global restructuring
The moves aim to save $1.3 billion annually by next year, streamline operations and increase focus on diabetes and obesity growth.
Teva wins FDA nod for first generic GLP-1 weight-loss drug
Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.
Novo Nordisk halves Ozempic price to $499 for US patients
As part of an effort to improve access to authentic versions of its GLP-1 medications, the drugmaker is cutting the cost of its popular diabetes drug.
Frier Levitt to host webinar on GLP-1 legal risks
The boutique health care firm will host a May 15 event exploring compounding, legal risks, FDA regulations and the growing role of payers in obesity treatment.
GLP-1 users spend less at the supermarket, Cornell study finds
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, including decreasing sales for certain kinds of foods.
